Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Blair William & Co. IL

Blair William & Co. IL raised its position in Becton, Dickinson and Company (NYSE:BDXFree Report) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,665 shares of the medical instruments supplier’s stock after acquiring an additional 1,930 shares during the quarter. Blair William & Co. IL’s holdings in Becton, Dickinson and Company were worth $13,874,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in BDX. Harbour Investments Inc. increased its position in Becton, Dickinson and Company by 2.9% in the 2nd quarter. Harbour Investments Inc. now owns 1,331 shares of the medical instruments supplier’s stock worth $351,000 after buying an additional 38 shares during the period. Townsend Asset Management Corp NC ADV increased its position in Becton, Dickinson and Company by 3.4% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 1,189 shares of the medical instruments supplier’s stock worth $314,000 after buying an additional 39 shares during the period. Glenview Trust Co increased its position in Becton, Dickinson and Company by 3.8% in the 2nd quarter. Glenview Trust Co now owns 1,096 shares of the medical instruments supplier’s stock worth $289,000 after buying an additional 40 shares during the period. Jeppson Wealth Management LLC increased its position in Becton, Dickinson and Company by 4.0% in the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after buying an additional 40 shares during the period. Finally, Ropes Wealth Advisors LLC increased its position in Becton, Dickinson and Company by 0.5% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 8,901 shares of the medical instruments supplier’s stock worth $2,350,000 after buying an additional 41 shares during the period. Hedge funds and other institutional investors own 86.72% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $243.75 on Monday. The stock’s fifty day moving average is $238.69 and its 200-day moving average is $253.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The stock has a market capitalization of $70.42 billion, a PE ratio of 57.76, a PEG ratio of 2.01 and a beta of 0.43. Becton, Dickinson and Company has a 52 week low of $228.62 and a 52 week high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.29. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.98 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post 12.95 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be issued a $0.95 dividend. The ex-dividend date is Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a yield of 1.56%. Becton, Dickinson and Company’s dividend payout ratio is presently 90.05%.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research reports. TheStreet cut Becton, Dickinson and Company from a “b” rating to a “c+” rating in a research report on Thursday, November 9th. Barclays boosted their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Morgan Stanley lowered their price objective on Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating on the stock in a research report on Monday, December 4th. Raymond James boosted their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Piper Sandler lowered their price objective on Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $279.17.

Read Our Latest Analysis on BDX

Insider Activity at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 2,156 shares of the company’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $238.47, for a total value of $514,141.32. Following the completion of the sale, the executive vice president now owns 4,120 shares in the company, valued at approximately $982,496.40. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.31% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.